Patents by Inventor Thomas Schurpf

Thomas Schurpf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20240016928
    Abstract: Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGF?1 in the treatment of disease that involve TGF?1 dysregulation.
    Type: Application
    Filed: August 1, 2023
    Publication date: January 18, 2024
    Inventors: Thomas Schurpf, Abhishek Datta, Gregory J. Carven, Constance Martin, Ashish Kalra, Kimberly Long, Alan Buckler
  • Compositions and methods for growth factor modulation
    Patent number: 11827698
    Abstract: Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-? superfamily of proteins.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: November 28, 2023
    Assignee: Scholar Rock, Inc.
    Inventors: Thomas Schurpf, Nagesh K. Mahanthappa, Michelle Straub
  • TGFbeta1-BINDING IMMUNOGLOBULINS AND USE THEREOF
    Publication number: 20230348583
    Abstract: Disclosed herein are immunoglobulins, such as antibodies, and antigen binding portions thereof, that specifically bind complexes of GARP-TGF?1, LTBP1-TGF?1, LTBP3-TGF?1, and/or LRRC33-TGF?1. The application also provides methods of use of these immunoglobulins for, for example, inhibiting TGF?1 activity, and treating subjects suffering from TGF?1-related disorders, such as cancer and fibrosis.
    Type: Application
    Filed: March 31, 2023
    Publication date: November 2, 2023
    Inventors: Thomas SCHURPF, Gregory J. CARVEN, Abhishek DATTA, Kimberly LONG
  • TGF?1-binding immunoglobulins and use thereof
    Patent number: 11643459
    Abstract: Disclosed herein are immunoglobulins, such as antibodies, and antigen binding portions thereof, that specifically bind complexes of GARP-TGF?1, LTBP1-TGF?1, LTBP3-TGF?1, and/or LRRC33-TGF?1. The application also provides methods of use of these immunoglobulins for, for example, inhibiting TGF?1 activity, and treating subjects suffering from TGF?1-related disorders, such as cancer and fibrosis.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: May 9, 2023
    Assignee: Scholar Rock, Inc.
    Inventors: Thomas Schurpf, Gregory J. Carven, Abhishek Datta, Kimberly Long
  • TGFB INHIBITORS AND USE THEREOF
    Publication number: 20230057012
    Abstract: Disclosed herein are novel inhibitors of TGF?1 activation with durable inhibitory effects. Methods directed to the selection of a suitable TGF? inhibitor for various disease conditions and patient populations are also provided.
    Type: Application
    Filed: January 11, 2021
    Publication date: February 23, 2023
    Inventors: Stefan Wawersik, Thomas Schurpf, Christopher Chapron, Sandeep Kumar, Adam Fogel
  • TGF-BETA INHIBITORS AND USE THEREOF
    Publication number: 20230050148
    Abstract: The present disclosure provides TGF? inhibitor therapy for treating immunosuppressive conditions, such as cancer. Selection of suitable therapy and patients who are likely to benefit from such therapy are also disclosed, as well as methods of treating cancer and methods of predicting and monitoring therapeutic response. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: January 11, 2021
    Publication date: February 16, 2023
    Inventors: Ashish Kalra, Thomas Schurpf, Adam Fogel, Christopher Brueckner, Alan Buckler, Constance Martin, Si Tuen Lee-Hoeflich
  • LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
    Publication number: 20220363741
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Application
    Filed: May 17, 2022
    Publication date: November 17, 2022
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich, JR.
  • LTBP complex-specific inhibitors of TGF? and uses thereof
    Patent number: 11365245
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: June 21, 2022
    Assignee: Scholar Rock, Inc.
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich, Jr.
  • LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
    Publication number: 20220064276
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Application
    Filed: November 19, 2021
    Publication date: March 3, 2022
    Inventors: Thomas SCHURPF, Justin W. JACKSON, George CORICOR, Abhishek DATTA, Stefan WAWERSIK, Christopher LITTLEFIELD, Adam FOGEL, Caitlin STEIN, Julia McCREARY, Matthew SALOTTO, Frederick STREICH, JR.
  • ISOFORM-SELECTIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20220064275
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: August 19, 2021
    Publication date: March 3, 2022
    Inventors: Abhishek DATTA, Allan CAPILI, Thomas SCHURPF, Constance MARTIN, Kevin B. DAGBAY, Christopher CHAPRON, Stefan WAWERSIK, Christopher LITTLEFIELD, Gregory J. CARVEN, Alan BUCKLER, Susan LIN, Justin W. JACKSON, Caitlin STEIN, Matthew SALOTTO, Andrew AVERY, Anthony COOPER
  • LTBP complex-specific inhibitors of TGF? and uses thereof
    Patent number: 11214614
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: January 4, 2022
    Assignee: Scholar Rock, Inc.
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich, Jr.
  • TGFß1 INHIBITORS AND USE THEREOF
    Publication number: 20210340238
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: July 11, 2019
    Publication date: November 4, 2021
    Inventors: Abhishek Datta, Thomas Schurpf, Allan Capili, Stefan Wawersik, Christopher Chapron, Christopher Littlefield, Gregory J. Carven, Kevin B. Dagbay, Susan Lin, Justin W. Jackson, Caitlin Stein
  • Isoform-selective TGF?1 inhibitors and use thereof
    Patent number: 11130803
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: September 28, 2021
    Assignee: Scholar Rock, Inc.
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Matthew Salotto, Andrew Avery, Anthony Cooper
  • COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION
    Publication number: 20210284722
    Abstract: Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-? superfamily of proteins.
    Type: Application
    Filed: March 9, 2021
    Publication date: September 16, 2021
    Inventors: Thomas Schurpf, Nagesh K. Mahanthappa, Michelle Straub
  • TGFBeta Antibodies, Methods and Uses
    Publication number: 20210277100
    Abstract: ProTGF?1-GARP complex-selective antibodies, polynucleotides capable of encoding the proTGF?1-GARP complex-selective antibodies or antigen-binding fragments, cells expressing proTGF?1-GARP complex-selective antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled proTGF?1-GARP complex-selective antibodies or antigen-binding fragments may be used to enhance an immune response in a subject, for example, against a cancer.
    Type: Application
    Filed: May 25, 2021
    Publication date: September 9, 2021
    Inventors: Gregory J. Carven, Thomas Schurpf, Katherine Turner
  • HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
    Publication number: 20210122814
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: July 11, 2019
    Publication date: April 29, 2021
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Andrew Avery, Anthony Cooper, Matthew Salotto
  • Compositions and methods for growth factor modulation
    Patent number: 10981981
    Abstract: Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-? superfamily of proteins.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: April 20, 2021
    Assignee: Scholar Rock, Inc.
    Inventors: Thomas Schurpf, Nagesh K. Mahanthappa, Michelle Straub
  • LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
    Publication number: 20210047396
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Application
    Filed: August 19, 2020
    Publication date: February 18, 2021
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich
  • LTBP COMPLEX-SPECIFIC INHIBITORS OF TGF-BETA 1 AND USES THEREOF
    Publication number: 20200231682
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen binding portions thereof, that selectively bind complexes of LTBP1-TGF?1 and/or LTBP3-TGF?1. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF?1 activation, and treating subjects suffering from TGF?1-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF?1 inhibitor for a subject in need thereof are also provided.
    Type: Application
    Filed: July 27, 2018
    Publication date: July 23, 2020
    Inventors: Thomas Schurpf, Christopher Littlefield, Gregory J. Carven, Abhishek Datta
  • LRRC33 INHIBITORS AND USE THEREOF
    Publication number: 20200181251
    Abstract: Disclosed herein are LRRC33 inhibiting agents and related methods and uses thereof. More specifically, therapeutic agents for inhibiting LRRC33 effects in vivo are provided. Such agents are useful for the treatment of various disorders involving cells expressing LRRC33 or LRRC33-containing complexes on the surface of cells.
    Type: Application
    Filed: May 9, 2018
    Publication date: June 11, 2020
    Inventors: Alan Buckler, Gregory J. Carven, Stefan Wawersik, Thomas Schurpf, Constance Martin, Abhishek Datta, Mark Allen Farmer